Inhibikase Therapeutics Receives Buy Rating and Increased Price Target from HC Wainwright Co
HC Wainwright & Co. has reiterated its Buy rating for Inhibikase Therapeutics (NASDAQ: IKT) on March 5, 2024, while raising ...
© 2024 Stocks Today
Tag: IKT
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools
-
The Future of Secure Communications: How Quantum-Resistant Encryption is Revolutionizing Wireless Technology
-
The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions
-
Unlocking Potential: How Recent Acquisitions in the Battery Technology Sector Are Reshaping the Energy Landscape